26 citations
,
June 2024 in “Frontiers in Immunology” The authors discussed that SOCS1 and SOCS3's inhibition of JAKs plays a significant role in the development of JAK inhibitor drugs for skin inflammatory diseases and malignancies.
70 citations
,
March 2008 in “Mechanisms of Ageing and Development” This review discusses genome maintenance mechanisms critical for preventing age-related diseases by preserving stem and progenitor cell potential, but reports no new empirical findings.
26 citations
,
October 2018 in “Clinical & Translational Oncology” This review outlines dermatological toxicities associated with targeted cancer therapies and immunotherapies, emphasizing the need for collaborative management by oncologists and dermatologists but reports no new clinical findings.
June 2025 in “British Journal of Clinical Pharmacology” This study highlights the significant impact of cutaneous side effects associated with anticancer therapies, emphasizing the need for proactive management to improve patient quality of life and treatment adherence.
June 2023 in “Skin Health and Disease” This editorial highlights recent progress in understanding chronic inflammatory skin diseases, leading to new treatments like JAK inhibitors for eczema and psoriasis, while emphasizing the journal's call for research on skin biology and aging.